J. Sagar Associates advised Motilal Oswal Private Equity, in respect of its investment of up to Rs. 240 crores in Molbio Diagnostics Private Limited. Molbio, along with its subsidiary Bigtec labs, has developed and commercialised Truenat, a point-of-care (PoC) molecular diagnostics platform using polymerase chain reaction (PCR) technology. Truenat can diagnose 22 infectious diseases, such as tuberculosis (TB), H1N1, dengue, HIV and hepatitis, among others. It has a pipeline for an additional 43 diseases, including Coronavirus and Middle East Respiratory Syndrome (MERS). Molbio is working closely with Central and State governments to support the national mission of TB eradication by 2025 and efficient diagnosis of H1N1, dengue, hepatitis B&C and other infectious diseases. JSA team comprised Partners Vikram Raghani and Manav Raheja along with Associate Gaurav Matta. Partner Soumitra Majumdar and Associates Rishabh Jain and Abhay Agarwal advised on the financing aspects of the transaction.